Great presentation yesterday by Prof Trent Munro and he has then followed through today with a great result.
Microba is in pole position to develop a microbiome based therapeutic for patients receiving immune checkpoint inhibitor therapy across a range of cancers. Only 30% of cancer patients respond to cancer drugs but combined with a microbiome based therapeutic it can increase that response rate substantially.
I can see Microba partnering up quickly with big pharma.
A US$30 bil opportuniity for Microba with a greater than 15% CAGR.
Ann: Positive first animal data for Cancer Program, page-2
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $78.37M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.5¢ | 17.0¢ | $1.92K | 11.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 90212 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 39670 | 2 |
View Market Depth
| Last trade - 12.17pm 23/07/2024 (20 minute delay) ? |
| MAP (ASX) Chart |